广信股份 20250820 摘要 2025 上半年广信股份业绩同比下滑 17%，主因草甘膦价格波动、国际 油价下调及关税政策不确定性，其中草甘膦价格在 5 月中旬开始上涨， 但此前公司以每吨 2.3 万元的价格销售，导致亏损和开工率降低。 广信股份二三季度营业成本下降超 1.5 亿元，主要得益于上游原材料价 格下降，特别是石油价格波动带来的整体成本降低。若石油价格维持稳 定，公司有望维持较低的营业成本。 草甘膦自 6 月以来价格强势，已达每吨 2.6 万元左右。一季度全行业亏 损，但随着涨价，公司开工率有所恢复。若供需稳定且全球经济形势稳 定，预计草甘膦市场将保持强劲，但需警惕行业竞争和国际形势不确定 性。 广信股份二季度消耗草甘膦库存约 5,000 吨，剩余两三千吨。检修预计 9 月底完成，新工艺加快投放市场。通过国内采购稳定客户关系。 敌草隆生产企业国内较少，竞争格局集中，供应相对稳定，但面临安全 事故和政策变化风险。 广信股份盈利稳定，满负荷运行，每季度平均产量约 2,500 吨，毛利率 维持在 30%以上。国内市场主要由广信股份、新安股份和江苏快达主导。 广信股份主力原药产品出口占销售总额约 1/3， ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company's Q2 performance met expectations, with a continued recovery in industry sentiment [1] - The agricultural pesticide industry is experiencing a recovery, with inventory depletion largely completed and downstream demand gradually improving [5] - The company is leveraging its integrated supply chain advantages to maintain stable profitability despite challenges in raw material prices and sales volume [5] Financial Data and Profit Forecast - Total revenue for 2025H1 was 1,890 million yuan, with a year-on-year decline of 17.4% [4] - The net profit attributable to the parent company for 2025H1 was 351 million yuan, down 15% year-on-year [4] - The company forecasts net profits of 740 million yuan, 902 million yuan, and 1,067 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 15, 12, and 10 [5][6] - The gross margin for Q2 was 30.92%, showing a year-on-year increase of 0.61 percentage points [5] Market Data - As of August 19, 2025, the closing price was 12.03 yuan, with a market capitalization of 10,951 million yuan [1] - The stock has a dividend yield of 2.24% based on the most recent dividend announcement [1] - The company’s price-to-book ratio is 1.1, indicating a reasonable valuation relative to its net assets [1]

Investment Rating - The investment rating for the chemical industry is "Positive" (maintained) [1] Core Insights - The report highlights that the agricultural chemical industry is undergoing a "Three-Year Action Plan" aimed at improving market order and curbing excessive competition, which is expected to enhance profitability and industry conditions by 2027 [4][5] - The global agricultural chemical market has entered a destocking phase since Q4 2022, with domestic production capacity being released, leading to a recovery in prices for certain agricultural chemicals [5] - The report identifies several key companies that are expected to benefit from the industry's recovery, including Yangnong Chemical, Limin Co., and Xingfa Group, among others [5] Summary by Sections Industry Trends - The agricultural chemical market has seen a decline in prices since 2021 due to supply-demand mismatches, but recent data indicates a potential rebound in prices for key products like glyphosate and chlorpyrifos [5][53] - Exports of herbicides, insecticides, and fungicides from China have shown significant year-on-year increases of 14%, 32%, and 24% respectively in the first half of 2025 [11][16] Regulatory Developments - The "Three-Year Action Plan" initiated by the China Pesticide Industry Association aims to address issues such as illegal production and excessive competition, with specific measures to enhance product quality and compliance [4][56] Company Performance - The report provides a forecast for various companies, indicating that Yangnong Chemical is expected to see a profit growth of 17.3% in 2025, while Limin Co. is projected to have a significant profit increase of 460.5% [56][58] - The report also lists companies with strong market positions and potential for growth, including Jiangshan Co. and Helilong [5][56]

Group 1: Securities Industry - The securities industry is experiencing a significant performance increase, with a projected net profit growth of 94% year-on-year for 31 listed brokers in H1 2025, driven by a recovery in the capital market and policy support [6][7][21] - The number of new A-share accounts opened in H1 2025 reached 12.6 million, a year-on-year increase of 32.8%, indicating heightened market participation [7] - Daily trading volume in H1 2025 increased by 61% year-on-year to 1.39 trillion yuan, reflecting improved market activity [7] - The underwriting of IPOs and refinancing in H1 2025 saw a year-on-year increase of 4% and 26%, respectively, with total underwriting amounts reaching 355 billion yuan and 6.326 trillion yuan [7] - The bond underwriting market also showed robust activity, with a total underwriting scale of 7.5 trillion yuan in H1 2025, up 22.3% year-on-year [7] - Mergers and acquisitions in the industry have led to significant profit increases, with Guotai Junan and Haitong Securities reporting net profit growth of 205%-218% in H1 2025 due to consolidation effects [8][21] - Compliance and risk control measures have been effectively implemented, allowing firms like Huaxi Securities to return to profitability, with expected net profit growth of 1025%-1354% in H1 2025 [9][21] Group 2: Food and Beverage Industry - The food and beverage sector saw a 0.68% increase last week, underperforming the CSI 300 index by 0.41 percentage points, ranking 14th among 31 sectors [12][13] - The liquor industry is under pressure, with June retail sales of tobacco and alcohol declining by 0.7% year-on-year, indicating weak demand [13] - Major liquor companies are expected to report varying degrees of decline in H1 2025, with traditional consumption scenarios struggling [13] - The beer sector is anticipated to recover, with low inventory levels and improved sales expected due to seasonal demand and cost reductions [14] - The snack segment is experiencing high growth, driven by strong product categories and new channel developments, particularly in health-oriented products [15][16] Group 3: Agricultural Chemicals Industry - Guangxin Co., a major player in the agricultural chemicals sector, is optimizing its integrated production chain based on phosgene, with a production capacity of 320,000 tons per year [18][19] - The agricultural chemicals market is currently at a relative bottom, with prices expected to rise as global inventory levels decrease and outdated capacities are phased out [19] - The company has a strong cash flow position, with 8.685 billion yuan in liquid assets, supporting its long-term development and cost optimization [19][20]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [7]. Core Views - The company is positioned at the bottom of the pesticide industry cycle, leveraging its integrated production chain based on phosgene to explore new opportunities [4]. - The overall pesticide prices are at a relatively low point, with expectations for recovery to enhance profitability [7]. - The company has a robust cash flow, which supports the upgrading of its industrial chain and optimizes costs [7]. Summary by Sections 1. Complete Industrial Chain Supports Rapid Development - The company is one of the largest domestic producers of pesticide raw materials and intermediates based on phosgene, forming a complete industrial chain from raw materials to intermediates to agricultural products [12]. - The company has a stable shareholding structure, with the actual controllers holding a high concentration of shares, which is beneficial for long-term development [17]. - The company has ample funds, with a total of 8.685 billion yuan in cash and other liquid assets by 2024, providing sufficient financial support for long-term construction and development [23]. 2. Steady Development of the Pesticide Sector - The pesticide sector is experiencing price recovery from a low point, which is expected to enhance profits [7]. - The company is a leading producer of the fungicides carbendazim and methyl thiophanate, with significant production capacity [32]. - The company is among the first in China to achieve production of the herbicide dicamba, holding a leading position in domestic production capacity [45]. 3. Leveraging Phosgene Resources for Industrial Chain Expansion - The company is a leader in the phosgene-based pesticide industry, with a high entry barrier for phosgene production [7]. - Phosgene resources are scarce, and the company has a diverse range of downstream products [7]. - Phosgene can be used to produce isocyanates, which have excellent performance in modified products, providing new directions for industrial development [7]. 4. Profit Forecast and Valuation - The company is expected to achieve total revenue of 50.21 billion yuan, 54.49 billion yuan, and 59.67 billion yuan from 2025 to 2027, with year-on-year growth rates of 8.15%, 8.52%, and 9.51% respectively [7]. - The net profit attributable to shareholders is projected to be 9.39 billion yuan, 11.18 billion yuan, and 12.26 billion yuan for the same period, with growth rates of 20.59%, 19.07%, and 9.62% respectively [7]. - The earnings per share (EPS) are expected to be 1.03 yuan, 1.23 yuan, and 1.35 yuan, corresponding to price-to-earnings (P/E) ratios of 11.17, 9.38, and 8.55 [7].

Summary of Key Points from the Conference Call on the Pesticide Industry Industry Overview - The conference call focused on the pesticide industry, particularly the implications of Bayer's legal issues related to glyphosate and the overall market dynamics affecting various pesticide products. Core Insights and Arguments - **Bayer's Glyphosate Lawsuit**: Bayer faces significant financial pressure from glyphosate lawsuits, potentially leading to its exit from the U.S. herbicide market. Chinese companies, as major glyphosate producers, need to monitor market changes and risks closely [1][3] - **Supply Tightness in Acetochlor**: Environmental restrictions and safety incidents have led to tight supply and significant price increases for acetochlor, benefiting major producers like Shandong Xianda and Hebei Lansheng, while smaller firms are also ramping up production to fill market gaps [1][4] - **Price Volatility in Fungicides**: The fungicide market has seen price fluctuations due to environmental shutdowns. For instance, the price of Mancozeb peaked at 38,000 yuan due to supply-demand imbalances, while other fungicides like Chlorothalonil are benefiting from global restocking demands [1][5] - **Strong Performance of Avermectin and Methomyl**: Avermectin and Methomyl have shown robust price stability, with Avermectin exceeding 510,000 yuan per ton, attributed to effective capacity utilization and production scheduling by companies [1][7] - **Bayer's Potential Bankruptcy Strategy**: Bayer may consider bankruptcy restructuring as a strategy to compel U.S. government intervention in glyphosate lawsuits. A shutdown of Bayer's glyphosate production could impact its 370,000-ton capacity and transgenic seed business [1][8] - **Market Consolidation Trends**: The domestic herbicide market is experiencing consolidation trends, with market shrinkage due to drought and reduced pest issues, prompting companies to seek development opportunities [1][35] Additional Important Insights - **Global Pesticide Demand Recovery**: The pesticide industry is witnessing a recovery in demand, driven by last year's low price levels and increased environmental regulations leading to production halts. The global pesticide destocking phase has ended, entering a restocking phase [2] - **Impact of Monsanto's Glyphosate Issues**: The glyphosate issues faced by Monsanto (now part of Bayer) have led to significant litigation costs, estimated at around $10 billion, affecting its stock and business operations. The domestic market is currently at a low price level, around 22,000 to 23,000 yuan [3] - **Acetochlor's Market Dynamics**: Acetochlor prices surged from 60,000 yuan to over 100,000 yuan due to supply disruptions caused by environmental issues and safety incidents [4] - **Fungicide Market Demand**: The demand for fungicides is expected to grow, with Brazil's procurement of Chlorothalonil increasing to 45,000 tons in 2024, reflecting a recovery from previous destocking phases [5][25] - **Pesticide Market Growth Projections**: The pesticide market is projected to see a demand increase of 10% to 20% in 2025 compared to 2024, indicating a positive growth outlook [26] This summary encapsulates the critical points discussed during the conference call, highlighting the current state and future outlook of the pesticide industry, particularly in relation to Bayer's challenges and market dynamics.

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of 14.4 CNY [1][6]. Core Views - The company is expected to benefit from a price turning point for its core product, Mancozeb, and is anticipated to see contributions from new products in the future [1][6]. - The agricultural pesticide industry is showing signs of recovery, with improved sales volumes and pricing expected in the coming periods [6][7]. Financial Summary - **Revenue Forecast**: - 2024A: 4,643 million CNY, -20.9% YoY - 2025E: 5,367 million CNY, +15.6% YoY - 2026E: 6,092 million CNY, +13.5% YoY - 2027E: 6,849 million CNY, +12.4% YoY [2][7] - **Net Profit Forecast**: - 2024A: 779 million CNY, -45.9% YoY - 2025E: 875 million CNY, +12.4% YoY - 2026E: 1,066 million CNY, +21.9% YoY - 2027E: 1,237 million CNY, +16.0% YoY [2][7] - **Earnings Per Share (EPS)**: - 2024A: 0.86 CNY - 2025E: 0.96 CNY - 2026E: 1.17 CNY - 2027E: 1.36 CNY [2][7] - **Valuation Ratios**: - Price-to-Earnings (P/E) ratio is projected to be 13, 11, 9, and 8 for 2024A, 2025E, 2026E, and 2027E respectively [2][7]. Market Performance - The company has experienced a significant decline of 34% over the past year, compared to the Shanghai Composite Index [5]. Product Insights - The company’s main pesticide raw materials saw a sales volume increase of 37.16% YoY in 2024, despite a price drop of 33.78% [6][7]. - The price of Mancozeb is expected to rise from 32,800 CNY/ton to 37,000 CNY/ton, indicating a positive trend for the company's performance [6][7]. Investment Recommendations - The company is positioned to leverage its integrated capabilities and cost advantages, with a strong return on equity (ROE) and significant cash reserves for capital expenditures [6][7]. - The adjusted profit expectations for 2025-2027 are 875 million CNY, 1,066 million CNY, and 1,237 million CNY respectively, with a corresponding P/E of 11, 9, and 8 [6][7].

Investment Rating - The investment rating for the company is "Buy" with a target price not specified [6] Core Views - The company's Q1 2025 performance met expectations, with revenue of 3.241 billion yuan, a year-on-year increase of 2.04%, and a net profit attributable to shareholders of 435 million yuan, a slight increase of 1.35% [1] - The industry is gradually stabilizing, and the company experienced good sales growth in Q1, particularly in its raw materials business, which was the main driver of revenue growth [1][2] - The company maintained good cost control, with a reduction in total expenses compared to the previous year, positively impacting net profit [3] - The company is advancing its projects in Liaoning, which are expected to optimize product layout and create new growth points for sustainable development [3] Financial Summary - For 2025-2027, the projected net profit attributable to the parent company is expected to be 1.47 billion yuan, 1.78 billion yuan, and 2 billion yuan respectively, reflecting a positive growth outlook [3] - The company's revenue for 2025 is estimated at 12.86 billion yuan, with a growth rate of 23.23% compared to 2024 [5] - The earnings per share (EPS) for 2025 is projected to be 3.61 yuan, with a price-to-earnings (P/E) ratio of 14.44 [5] Sales and Pricing - In Q1, the company achieved sales volumes of 28,700 tons for raw materials and 15,400 tons for formulations, representing increases of 14.8% and 2.8% year-on-year respectively [2] - The average prices for raw materials and formulations in Q1 were 63,000 yuan and 56,600 yuan, showing declines of 8.8% and 1.6% year-on-year [2] Cost Control and Project Development - The company reduced its sales expenses by approximately 1.65 million yuan year-on-year, while management and R&D expenses increased [3] - The first phase of the Liaoning project has been completed and is in the process of trial production, with several products already meeting quality standards [3]